Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 3032-3046

  Liu, Guoxiang ^a   Yu, Jia ^a   Ding, Jinhui ^a   Xie, Chengsong ^a   Sun, Lixin ^a   Rudenko, Iakov ^a   Zheng, Wang ^a   Sastry, Namratha ^a   Luo, Jing ^b   Rudow, Gay ^c   Troncoso, Juan C ^c   Cai, Huaibin ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b BEIJING NORMAL UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALPHA SYNUCLEIN; CAMPTOTHECIN; GLUTAMIC ACID; OLIGOMER; UNCLASSIFIED DRUG;

ALDH1A1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CELL DEATH; CELL LOSS; CELL SUBPOPULATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EVALUATION STUDY; FEMALE; GENE; GENE DELETION; HUMAN; HUMAN TISSUE; LOCOMOTION; MALE; MOUSE; MURINE MODEL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; REARING; ROTAROD TEST; SUBSTANTIA NIGRA PARS COMPACTA; TRANSGENIC MOUSE;

ALDEHYDE DEHYDROGENASE; ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTANT PROTEINS; MUTATION, MISSENSE; NERVE DEGENERATION; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; RECOMBINANT PROTEINS; SUBSTANTIA NIGRA;

EID: 84903763532     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72176     Document Type: Article

References (46)

1. Schapira AH. Pathogenesis of Parkinson?s disease. Baillieres Clin Neurol. 1997;6(1):15-36.
2. Hirsch EC, Graybiel AM, Agid Y. Selective vulnerability of pigmented dopaminergic neurons in Parkinson?s disease. Acta Neurol Scand Suppl. 1989;126:19-22.
3. Fearnley JM, Lees AJ. Ageing and Parkinson?s disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5):2283-2301.
4. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson?s disease. Brain. 1999;122(pt 8):1437-1448.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388(6645):839-840.
6. Polymeropoulos MH, et al. Mutation in the α-synuclein gene identified in families with Parkinson?s disease. Science. 1997;276(5321):2045- 2047.
7. Singleton AB, et al. α-Synuclein locus triplication causes Parkinson?s disease. Science. 2003; 302(5646):841.
8. Simon-Sanchez J, et al. Genome-wide association study reveals genetic risk underlying Parkinson?s disease. Nat Genet. 2009;41(12):1308-1312.
9. Satake W, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson?s disease. Nat Genet. 2009;41(12):1303-1307.
10. Lin X, et al. Conditional expression of Parkinson?s disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci. 2012;32(27):9248-9264.
11. McCaffery P, Drager UC. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci U S A. 1994;91(16):7772-7776.
12. Marchitti SA, Deitrich RA, Vasiliou V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol Rev. 2007;59(2):125-150.
13. Rees JN, Florang VR, Eckert LL, Doorn JA. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem Res Toxicol. 2009;22(7):1256-1263.
14. Fitzmaurice AG, et al. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci U S A. 2013;110(2):636-641.
15. Anderson DW, Schray RC, Duester G, Schneider JS. Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res. 2011;1408:81-87.
16. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson?s disease. PLoS One. 2012;7(2):e31522.
17. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Lansbury PT Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science. 2001;294(5545):1346-1349.
18. Burke WJ, et al. Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115(2):193-203.
19. Neumann M, et al. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J Clin Invest. 2002; 110(10):1429-1439.
20. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci. 2007;27(12):3338-3346.
21. Cremades N, et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell. 2012;149(5):1048-1059.
22. Galter D, Buervenich S, Carmine A, Anvret M, Olson L. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson?s disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis. 2003;14(3):637-647.
23. Ouimet CC, Miller PE, Hemmings HC, Hemmings HC Jr, Walaas SI, Greengard P. DARPP-32, a dopamine-and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamineinnervated brain regions. III. Immunocytochemical localization. J Neurosci. 1984;4(1):111-124.
24. Fan X, et al. Targeted disruption of Aldh1a1 (Raldh1) provides evidence for a complex mechanism of retinoic acid synthesis in the developing retina. Mol Cell Biol. 2003;23(13):4637-4648.
25. Jinsmaa Y, et al. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson?s disease. Chem Biol Interact. 2011;192(1-2):118-121.
26. Kong D, Kotraiah V. Modulation of aldehyde dehydrogenase activity affects (+/-)-4-hydroxy-2E-nonenal (HNE) toxicity and HNE-protein adduct levels in PC12 cells. J Mol Neurosci. 2012;47(3):595-603.
27. Bilsland J, et al. Caspase inhibitors attenuate 1-methyl-4- phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons. J Neurosci. 2002;22(7):2637-2649.
28. Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci. 1995;15(5 pt 1):3318-3327.
29. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol. 1996;134(3):757-770.
30. Lin X, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson?s-disease-related mutant alpha-synuclein. Neuron. 2009;64(6):807-827.
31. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson?s disease. Mov Disord. 2013;28(1):41-50.
32. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson?s disease. Lancet Neurol. 2007; 6(10):933-938.
33. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson?s disease. J Biol Chem. 2013;288(15):10736-10741.
34. Sulzer D. α-Synuclein and cytosolic dopamine: stabilizing a bad situation. Nat Med. 2001;7(12):1280-1282.
35. Goldstein DS, et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson?s disease. J Neurochem. 2013;126(5):591-603.
36. Kurz A, et al. A53T-α-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One. 2010;5(7):e11464.
37. Lam HA, et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein. J Neurosci Res. 2011;89(7):1091-1102.
38. Jacobs FM, et al. Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development. 2007;134(14):2673- 2684.
39. Luk KC, et al. The transcription factor Pitx3 is expressed selectively in midbrain dopaminergic neurons susceptible to neurodegenerative stress. J Neurochem. 2013;125(6):932-943.
40. Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274(5293):1678-1683.
41. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. 3rd ed. Waltham, Massachusetts, USA: Academic Press; 2008.
42. Beach TG, et al. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank. 2008;9(3):229-245.
43. Mai JK, Paxinos G, Voss T. Atlas Of The Human Brain. 3rd ed. Waltham, Massachusetts, USA: Academic Press; 2007.
44. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med. 2005;11(11):1214-1221.
45. Chandran JS, et al. Progressive behavioral deficits in DJ-1-deficient mice are associated with normal nigrostriatal function. Neurobiol Dis. 2008; 29(3):505-514.
46. Levites Y, et al. Intracranial adeno-associated virusmediated delivery of anti-pan amyloid β, amyloid β40, and amyloid β42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci. 2006;26(46):11923-11928.